{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:36:16Z","timestamp":1788568576067,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"IMMY Investigator Initiated Research"},{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Galactomannan (GM) testing using Platelia Aspergillus enzyme immunoassay (Platelia AGM) from bronchoalveolar lavage fluid (BALF) aids in early diagnosis of invasive pulmonary aspergillosis (IPA). Globally, only a minority of laboratories have the capability to perform on-site GM testing, necessitating accessible and affordable alternatives. Hence, we conducted a comparative evaluation of the new clarus Aspergillus GM enzyme immunoassay prototype (clarus AGM prototype) with Platelia AGM using BALF samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a single-center, prospective, cross-sectional study, where Platelia AGM testing was routinely performed followed by clarus AGM prototype testing in those with true positive or true negative AGM test results according to the 2020 EORTC\/MSG and the 2024 FUNDICU consensus definitions. Descriptive statistics, ROC curve analysis, and Spearman\u2019s correlation analysis were used to evaluate analytical performance of the clarus AGM prototype assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study enrolled 259 adult patients, of which 53 (20%) were classified as probable IPA, while 206 did not fulfill IPA-criteria. Spearman's correlation analysis revealed a strong correlation between the two assays (rho\u2009=\u20090.727,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The clarus AGM prototype had a sensitivity of 96% (51\/53) and a specificity of 74% (153\/206) for differentiating probable versus no IPA when using the manufacturer recommended cut-off. ROC curve analysis showed an AUC of 0.936 (95% CI 0.901\u20130.971) for the clarus AGM prototype, while the Platelia AGM yielded an AUC of 0.918 (95% CI 0.876\u20130.959).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clarus AGM prototype demonstrated a strong correlation and promising test performance, comparable to Platelia AGM, rendering it a viable alternative in patients at risk of IPA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11046-024-00876-9","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T08:01:34Z","timestamp":1721289694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative Analysis of the Clarus Aspergillus Galactomannan Enzyme Immunoassay Prototype for the Diagnosis of Invasive Pulmonary Aspergillosis in Bronchoalveolar Lavage Fluid"],"prefix":"10.1007","volume":"189","author":[{"given":"Sarah","family":"Sedik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Dichtl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Prattes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Pr\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1653-2824","authenticated-orcid":false,"given":"Martin","family":"Hoenigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"876_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13449","author":"M Egger","year":"2022","unstructured":"Egger M, Hoenigl M, Thompson GR 3rd, Carvalho A, Jenks JD. Let\u2019s talk about sex characteristics - as a risk factor for invasive fungal diseases. Mycoses. 2022. https:\/\/doi.org\/10.1111\/myc.13449.","journal-title":"Mycoses"},{"key":"876_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(23)00692-8","author":"DW Denning","year":"2024","unstructured":"Denning DW. Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 2024. https:\/\/doi.org\/10.1016\/s1473-3099(23)00692-8.","journal-title":"Lancet Infect Dis"},{"key":"876_CR3","doi-asserted-by":"publisher","unstructured":"Jenks JD, Prattes J, Wurster S, Sprute R, Seidel D, Oliverio M, Egger M, Del Rio C, Sati H, Cornely OA, Thompson GR, 3rd, Kontoyiannis DP, Hoenigl M. 2023. Social determinants of health as drivers of fungal disease. eClinicalMedicine 66. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102325.","DOI":"10.1016\/j.eclinm.2023.102325"},{"key":"876_CR4","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","volume":"21","author":"P Koehler","year":"2021","unstructured":"Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, Klimko N, Lass-Fl\u00f6rl C, Oladele RO, Vinh DC, Zhu LP, B\u00f6ll B, Br\u00fcggemann R, Gangneux JP, Perfect JR, Patterson TF, Persigehl T, Meis JF, Ostrosky-Zeichner L, White PL, Verweij PE, Cornely OA. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21:e149\u201362.","journal-title":"Lancet Infect Dis"},{"key":"876_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1128\/CMR.12.2.310","volume":"12","author":"JP Latg\u00e9","year":"1999","unstructured":"Latg\u00e9 JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev. 1999;12:310\u201350.","journal-title":"Clin Microbiol Rev"},{"key":"876_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/thoraxjnl-2014-206291","volume":"70","author":"C Kosmidis","year":"2015","unstructured":"Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015;70:270\u20137.","journal-title":"Thorax"},{"key":"876_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0891-5520(02)00035-1","volume":"16","author":"KA Marr","year":"2002","unstructured":"Marr KA, Patterson T, Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am. 2002;16:875\u201394.","journal-title":"Infect Dis Clin North Am"},{"key":"876_CR8","doi-asserted-by":"publisher","first-page":"100115","DOI":"10.1016\/j.simyco.2021.100115","volume":"100","author":"A Arastehfar","year":"2021","unstructured":"Arastehfar A, Carvalho A, Houbraken J, Lombardi L, Garcia-Rubio R, Jenks JD, Rivero-Menendez O, Aljohani R, Jacobsen ID, Berman J, Osherov N, Hedayati MT, Ilkit M, Armstrong-James D, Gabald\u00f3n T, Meletiadis J, Kostrzewa M, Pan W, Lass-Fl\u00f6rl C, Perlin DS, Hoenigl M. Aspergillus fumigatus and aspergillosis: from basics to clinics. Stud Mycol. 2021;100:100115\u2013100115.","journal-title":"Stud Mycol"},{"key":"876_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13637","author":"Z Hashim","year":"2023","unstructured":"Hashim Z, Nath A, Khan A, Gupta M, Kumar A, Chatterjee R, Dhiman RK, Hoenigl M, Tripathy NK. Effect of glucocorticoids on the development of COVID-19-associated pulmonary aspergillosis: a meta-analysis of 21 studies and 5174 patients. Mycoses. 2023. https:\/\/doi.org\/10.1111\/myc.13637.","journal-title":"Mycoses"},{"key":"876_CR10","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00134-021-06510-2","volume":"47","author":"J Prattes","year":"2021","unstructured":"Prattes J, Koehler P, Hoenigl M. COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges. Intensive Care Med. 2021;47:1339\u201340.","journal-title":"Intensive Care Med"},{"key":"876_CR11","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/s41564-022-01172-2","volume":"7","author":"M Hoenigl","year":"2022","unstructured":"Hoenigl M, Seidel D, Sprute R, Cunha C, Oliverio M, Goldman GH, Ibrahim AS, Carvalho A. COVID-19-associated fungal infections. Nat Microbiol. 2022;7:1127\u201340.","journal-title":"Nat Microbiol"},{"key":"876_CR12","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.cmi.2021.08.014","volume":"28","author":"J Prattes","year":"2022","unstructured":"Prattes J, Wauters J, Giacobbe DR, Salmanton-Garc\u00eda J, Maertens J, Bourgeois M, Reynders M, Rutsaert L, Van Regenmortel N, Lormans P, Feys S, Reisinger AC, Cornely OA, Lahmer T, Valerio M, Delhaes L, Jabeen K, Steinmann J, Chamula M, Bassetti M, Hatzl S, Rautemaa-Richardson R, Koehler P, Lagrou K, Hoenigl M, Debaveye Y, Miceli MH, Tudesq J-J, Paul G, Krause R, Linhofer M, Frost J, Zechner P, Kochanek M, Eller P, Jenks JD, Volpi S, Bellanger A-P, White PL, Goldman GH, Bowyer P, Rokas A, Gago S, Pelosi P, Robba C, Gangneux J-P, Lass-Floerl C, Machado M, Mu\u00f1oz P. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients\u2014a multinational observational study by the European Confederation of Medical Mycology. Clin Microbiol Infect. 2022;28:580\u20137.","journal-title":"Clin Microbiol Infect"},{"key":"876_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11046-024-00852-3","volume":"189","author":"M Hoenigl","year":"2024","unstructured":"Hoenigl M, Enoch DA, Wichmann D, Wyncoll D, Cortegiani A. Exploring European consensus about the remaining treatment challenges and subsequent opportunities to improve the management of invasive fungal infection (IFI) in the Intensive Care Unit. Mycopathologia. 2024;189:41.","journal-title":"Mycopathologia"},{"key":"876_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.7326\/0003-4819-86-5-539","volume":"86","author":"J Aisner","year":"1977","unstructured":"Aisner J, Wiernik PH, Schimpff SC. Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med. 1977;86:539\u201343.","journal-title":"Ann Intern Med"},{"key":"876_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.03.006","author":"L Kriegl","year":"2024","unstructured":"Kriegl L, Egger M, Boyer J, Hoenigl M, Krause R. New treatment options for critically important WHO fungal priority pathogens. Clin Microbiol Infect. 2024. https:\/\/doi.org\/10.1016\/j.cmi.2024.03.006.","journal-title":"Clin Microbiol Infect"},{"key":"876_CR16","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases Society of America. Clin Infect Dis. 2016;63:e1\u201360.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"876_CR17","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Fl\u00f6rl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Br\u00fcggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, L\u00f6ffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sink\u00f3 J, Skiada A, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1\u201338.","journal-title":"Clin Microbiol Infect"},{"key":"876_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11046-024-00831-8","volume":"189","author":"R Aerts","year":"2024","unstructured":"Aerts R, Rica\u00f1o-Ponce I, Bruno M, Mercier T, Rosati D, Maertens J, Kumar V, Carvalho A, Netea MG, Hoenigl M. circulatory inflammatory proteins as early diagnostic biomarkers for invasive aspergillosis in patients with hematologic malignancies-an exploratory study. Mycopathologia. 2024;189:24.","journal-title":"Mycopathologia"},{"key":"876_CR19","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1093\/cid\/ciaa1786","volume":"72","author":"T Mercier","year":"2021","unstructured":"Mercier T, Castagnola E, Marr KA, Wheat LJ, Verweij PE, Maertens JA. Defining galactomannan positivity in the updated EORTC\/MSGERC consensus definitions of invasive fungal diseases. Clin Infect Dis. 2021;72:S89\u201394.","journal-title":"Clin Infect Dis"},{"key":"876_CR20","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2019","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH, Sorrell TC, Bassetti M, Akan H, Alexander BD, Andes D, Azoulay E, Bialek R, Bradsher RW Jr, Bretagne S, Calandra T, Caliendo AM, Castagnola E, Cruciani M, Cuenca-Estrella M, Decker CF, Desai SR, Fisher B, Harrison T, Heussel CP, Jensen HE, Kibbler CC, Kontoyiannis DP, Kullberg B-J, Lagrou K, Lamoth F, Lehrnbecher T, Loeffler J, Lortholary O, Maertens J, Marchetti O, Marr KA, Masur H, Meis JF, Morrisey CO, Nucci M, Ostrosky-Zeichner L, Pagano L, Patterson TF, Perfect JR, Racil Z, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2019;71:1367\u201376.","journal-title":"Clin Infect Dis"},{"key":"876_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106718:106718","author":"J Salmanton-Garc\u00eda","year":"2023","unstructured":"Salmanton-Garc\u00eda J, Au WY, Hoenigl M, Chai LYA, Badali H, Basher A, Brockhoff RA, Chen SC, Chindamporn A, Chowdhary A, Heath C, Jabeen K, Lee J, Matar M, Taj-Aldeen SJ, Tan BH, Uno K, Wahyuningsih R, Zhu LP, Chakrabarti A, Cornely OA. The current state of laboratory mycology in Asia\/Pacific: a survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM). Int J Antimicrob Agents. 2023. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106718:106718.","journal-title":"Int J Antimicrob Agents"},{"key":"876_CR22","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/S2666-5247(22)00261-0","volume":"4","author":"J Salmanton-Garc\u00eda","year":"2023","unstructured":"Salmanton-Garc\u00eda J, Hoenigl M, Gangneux JP, Segal E, Alastruey-Izquierdo A, Arikan Akdagli S, Lagrou K, \u00d6zenci V, Vena A, Cornely OA. The current state of laboratory mycology and access to antifungal treatment in Europe: a European Confederation of Medical Mycology survey. Lancet Microbe. 2023;4:e47\u201356.","journal-title":"Lancet Microbe"},{"key":"876_CR23","doi-asserted-by":"crossref","unstructured":"Lass-Fl\u00f6rl C, Samardzic E, Knoll M. 2021. Serology anno 2021\u2014fungal infections: from invasive to chronic, vol 27, p 1230\u20131241.","DOI":"10.1016\/j.cmi.2021.02.005"},{"key":"876_CR24","doi-asserted-by":"publisher","first-page":"e0021522","DOI":"10.1128\/jcm.00215-22","volume":"60","author":"M Egger","year":"2022","unstructured":"Egger M, Penziner S, Dichtl K, Gornicec M, Kriegl L, Krause R, Khong E, Mehta S, Vargas M, Gianella S, Porrachia M, Jenks JD, Venkataraman I, Hoenigl M. Performance of the euroimmun aspergillus antigen ELISA for the diagnosis of invasive pulmonary aspergillosis in bronchoalveolar lavage fluid. J Clin Microbiol. 2022;60:e0021522.","journal-title":"J Clin Microbiol"},{"key":"876_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2023.2257597","author":"R Aerts","year":"2023","unstructured":"Aerts R, Autier B, Gornicec M, Prattes J, Lagrou K, Gangneux JP, Hoenigl M. Point-of-care testing for viral-associated pulmonary aspergillosis. Expert Rev Mol Diagn. 2023. https:\/\/doi.org\/10.1080\/14737159.2023.2257597.","journal-title":"Expert Rev Mol Diagn"},{"key":"876_CR26","doi-asserted-by":"publisher","first-page":"e1737","DOI":"10.1093\/cid\/ciaa1281","volume":"73","author":"JD Jenks","year":"2021","unstructured":"Jenks JD, Prattes J, Frank J, Spiess B, Mehta SR, Boch T, Buchheidt D, Hoenigl M. Performance of the bronchoalveolar lavage fluid aspergillus galactomannan lateral flow assay with cube reader for diagnosis of invasive pulmonary aspergillosis: a multicenter cohort study. Clin Infect Dis. 2021;73:e1737\u201344.","journal-title":"Clin Infect Dis"},{"key":"876_CR27","doi-asserted-by":"publisher","first-page":"e0168921","DOI":"10.1128\/JCM.01689-21","volume":"60","author":"B Autier","year":"2022","unstructured":"Autier B, Prattes J, White PL, Valerio M, Machado M, Price J, Egger M, Gangneux JP, Hoenigl M. Aspergillus lateral flow assay with digital reader for the diagnosis of COVID-19-associated pulmonary aspergillosis (CAPA): a multicenter study. J Clin Microbiol. 2022;60:e0168921.","journal-title":"J Clin Microbiol"},{"key":"876_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-024-07341-7","author":"M Bassetti","year":"2024","unstructured":"Bassetti M, Giacobbe DR, Agvald-Ohman C, Akova M, Alastruey-Izquierdo A, Arikan-Akdagli S, Azoulay E, Blot S, Cornely OA, Cuenca-Estrella M, de Lange DW, De Rosa FG, De Waele JJ, Dimopoulos G, Garnacho-Montero J, Hoenigl M, Kanj SS, Koehler P, Kullberg BJ, Lamoth F, Lass-Fl\u00f6rl C, Maertens J, Martin-Loeches I, Mu\u00f1oz P, Poulakou G, Rello J, Sanguinetti M, Taccone FS, Timsit JF, Torres A, Vazquez JA, Wauters J, Asperges E, Cortegiani A, Grecchi C, Karaiskos I, Le Bihan C, Mercier T, Mortensen KL, Peghin M, Rebuffi C, Tejada S, Vena A, Zuccaro V, Scudeller L, Calandra T. Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM. Intensive Care Med. 2024. https:\/\/doi.org\/10.1007\/s00134-024-07341-7.","journal-title":"Intensive Care Med"},{"key":"876_CR29","unstructured":"Anonymous. 2023. clarus ASPERGILLUS GM ENZYME IMMUNOASSAY."},{"key":"876_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myz079:myz079","author":"T Mercier","year":"2019","unstructured":"Mercier T, Dunbar A, de Kort E, Schauwvlieghe A, Reynders M, Guldentops E, Blijlevens NMA, Vonk AG, Rijnders B, Verweij PE, Lagrou K, Maertens J. Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: a comparative multicenter study. Med Mycol. 2019. https:\/\/doi.org\/10.1093\/mmy\/myz079:myz079.","journal-title":"Med Mycol"},{"key":"876_CR31","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1128\/CVI.00068-08","volume":"15","author":"CR Thornton","year":"2008","unstructured":"Thornton CR. Development of an Immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol. 2008;15:1095\u2013105.","journal-title":"Clin Vaccine Immunol"},{"key":"876_CR32","doi-asserted-by":"publisher","first-page":"e464","DOI":"10.1016\/S2666-5247(21)00190-7","volume":"3","author":"C Driemeyer","year":"2022","unstructured":"Driemeyer C, Falci DR, Oladele RO, Bongomin F, Ocansey BK, Govender NP, Hoenigl M, Gangneux JP, Lass-Fl\u00f6rl C, Cornely OA, Alanio A, Guinea J, Morrissey CO, Rautemaa-Richardson R, Chakrabarti A, Meis JF, Bruns C, Stemler J, Pasqualotto AC. The current state of clinical mycology in Africa: a European confederation of medical mycology and international society for human and animal mycology survey. Lancet Microbe. 2022;3:e464\u201370.","journal-title":"Lancet Microbe"},{"key":"876_CR33","doi-asserted-by":"publisher","first-page":"e00074","DOI":"10.1128\/cmr.00074-23","volume":"37","author":"M Hoenigl","year":"2024","unstructured":"Hoenigl M, Arastehfar A, Arendrup MC, Br\u00fcggemann R, Carvalho A, Chiller T, Chen S, Egger M, Feys S, Gangneux J-P, Gold JAW, Groll AH, Heylen J, Jenks JD, Krause R, Lagrou K, Lamoth F, Prattes J, Sedik S, Wauters J, Wiederhold NP, Thompson GR. Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease. Clin Microbiol Rev. 2024;37:e00074-e123.","journal-title":"Clin Microbiol Rev"},{"key":"876_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01229-21:Jcm0122921","author":"M Erg\u00fcn","year":"2021","unstructured":"Erg\u00fcn M, Br\u00fcggemann RJM, Alanio A, Delli\u00e8re S, Arkel A, Bentvelsen RG, Rijpstra T, Sar-van der Brugge S, Lagrou K, Janssen NAF, Buil JB, van Dijk K, Melchers WJG, Reijers MHE, Schouten JA, Wauters J, Cordey A, Soni S, White PL, van de Veerdonk FL, Verweij PE. Aspergillus test profiles and mortality in critically-ill COVID-19 patients. J Clin Microbiol. 2021. https:\/\/doi.org\/10.1128\/jcm.01229-21:Jcm0122921.","journal-title":"J Clin Microbiol"},{"key":"876_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3109\/1040841X.2013.804033","volume":"41","author":"SC Heng","year":"2015","unstructured":"Heng SC, Morrissey O, Chen SC, Thursky K, Manser RL, Nation RL, Kong DC, Slavin M. Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis. Crit Rev Microbiol. 2015;41:124\u201334.","journal-title":"Crit Rev Microbiol"},{"key":"876_CR36","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1186\/s13054-020-03367-7","volume":"24","author":"T Mercier","year":"2020","unstructured":"Mercier T, Dunbar A, Veldhuizen V, Holtappels M, Schauwvlieghe A, Maertens J, Rijnders B, Wauters J. Point of care aspergillus testing in intensive care patients. Crit Care. 2020;24:642.","journal-title":"Crit Care"},{"key":"876_CR37","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/myc.12881","volume":"62","author":"JD Jenks","year":"2019","unstructured":"Jenks JD, Mehta SR, Taplitz R, Aslam S, Reed SL, Hoenigl M. Point-of-care diagnosis of invasive aspergillosis in non-neutropenic patients: aspergillus galactomannan lateral flow assay versus aspergillus-specific lateral flow device test in bronchoalveolar lavage. Mycoses. 2019;62:230\u20136.","journal-title":"Mycoses"},{"key":"876_CR38","doi-asserted-by":"publisher","first-page":"e13756","DOI":"10.1111\/myc.13756","volume":"67","author":"J Boyer","year":"2024","unstructured":"Boyer J, Sedik S, Egger M, Dichtl K, Prattes J, Kriegl L, Krause R, Pr\u00fcller F, Hoenigl M. Performance of the clarus Aspergillus galactomannan enzyme immunoassay prototype for the diagnosis of invasive pulmonary aspergillosis in serum. Mycoses. 2024;67:e13756.","journal-title":"Mycoses"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-024-00876-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11046-024-00876-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-024-00876-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T08:16:56Z","timestamp":1724401016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11046-024-00876-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["876"],"URL":"https:\/\/doi.org\/10.1007\/s11046-024-00876-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4275634\/v1","asserted-by":"object"}]},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.H. received research funding from Gilead, Astellas, MSD, IMMY, Pulmocide, Shionogi, Melinta, Mundipharma, Scynexis, F2G and Pfizer, all unrelated to the submitted work. J.P. holds the position of President at the Austrian Society of Medical Mycology, received speaker fees from Gilead, Pfizer, Swedish Orphan BioVitrum, Associates of Cape Cod and is stockholder of AbbVie Inc. and Novo Nordisk\u2014all outside of the submitted work. K.D. received research funding from Euroimmun Medizinische Labordiagnostika and FUJUFILM Wako Chemicals Europe outside of the submitted work. All other authors declare no conflict of interest for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"67"}}